Ganaplacide/lumefantrine

Small molecule

Also known as KLU156

Phase 3Mechanism not established
Phase 3topline reported

Evidence outlook · registrational

Malaria: topline reported 2025-11-12

No completed mid-stage readout is on record. The sponsor reported topline results on 2025-11-12 (Phase III KALUMA trial of GanLum meets primary endpoint). The announcement is listed under Regulatory events.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (1)
Malaria
NCT05842954 · Novartis Pharmaceuticals
2024-03-07 – 2025-11-25 · Uncomplicated Plasmodium Falciparum Malaria
What this study did
Phase 2 (3)
Malaria
NCT07811908 · Novartis Pharmaceuticals
2026-02-12 – 2027-02-18 · Uncomplicated Plasmodium Falciparum Malaria
What this study did
NCT05750628 · Novartis Pharmaceuticals
2024-01-23 – 2026-06-23 · Uncomplicated Plasmodium Falciparum Malaria
What this study did
NCT07235033 · Novartis Pharmaceuticals
2024-01-23 – 2025-03-19 · Uncomplicated Plasmodium Falciparum Malaria
What this study did

Competitive landscape

This drug's own stage for Malaria: Phase 3. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Ganaplacide / Lumefantrine: this drugPhase 3Small molecule—not yet gradedNo reviewed efficacy summary in this indication
CipargaminPhase 2Small moleculePfATP4not yet gradedNo reviewed efficacy summary in this indication
GSK3772701Phase 2Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
GSK4024484Phase 1Undisclosed—not yet gradedNo reviewed efficacy summary in this indication
INE963
Phase 1(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication
GSK4425689
—(overall)
UndisclosedCircumsporozoite protein (CSP)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Ganaplacide/lumefantrine to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
February 2027 (1)
Phase 2MalariaRecruiting
Est. primary completion 2027-02-04 · NCT07811908 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

12 November 2025Topline resultPhase III KALUMA trial of GanLum meets primary endpoint